Europe Dengue Treatment Market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 OBJECTIVES OF THE STUDY
• 1.2 MARKET DEFINITION
• 1.3 OVERVIEW OF THE EUROPE DENGUE TREATMENT MARKET
• 1.4 CURRENCY AND PRICING
• 1.5 LIMITATIONS
• 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

• 2.1 MARKETS COVERED
• 2.2 GEOGRAPHICAL SCOPE
• 2.3 YEARS CONSIDERED FOR THE STUDY
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
• 2.6 MULTIVARIATE MODELLING
• 2.7 MARKET APPLICATION COVERAGE GRID
• 2.8 PRODUCT LIFELINE CURVE
• 2.9 DBMR MARKET POSITION GRID
• 2.10 VENDOR SHARE ANALYSIS
• 2.11 SECONDARY SOURCES
• 2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 PESTEL ANALYSIS
• 4.2 PORTER'S FIVE FORCES

5 EUROPE DENGUE TREATMENT MARKET: REGULATIONS

• 5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT
• 5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT
• 5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK
• 5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE
• 5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK

6 MARKET OVERVIEW

• 6.1 DRIVERS
  • 6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT
  • 6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES
  • 6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS
  • 6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES
• 6.2 RESTRAINTS
  • 6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES
  • 6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE
  • 6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE
• 6.3 OPPORTUNITIES
  • 6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET
  • 6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT
  • 6.3.3 RISING R&D INVESTMENT AND ACTIVITIES
• 6.4 CHALLENGES
  • 6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS
  • 6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS

7 EUROPE DENGUE TREATMENT MARKET, BY STRAINS

• 7.1 OVERVIEW
• 7.2 DENV-2
• 7.3 DENV-3
• 7.4 DENV-1
• 7.5 DENV-4
• 7.6 OTHERS

8 EUROPE DENGUE TREATMENT MARKET, BY TYPE

• 8.1 OVERVIEW
• 8.2 VACCINES
  • 8.2.1 DENGVAXIA (CYD-TDV)
  • 8.2.2 QDENGA
• 8.3 ACETAMINOPHEN
  • 8.3.1 PARENTERAL
  • 8.3.2 ORAL
  • 8.3.3 OTHER

9 EUROPE DENGUE TREATMENT MARKET, BY SEVERITY

• 9.1 OVERVIEW
• 9.2 MILD TO MODERATE DENGUE
• 9.3 SEVERE DENGUE

10 EUROPE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

• 10.1 OVERVIEW
• 10.2 PARENTERAL
  • 10.2.1 SUB-CUTANEOUS
  • 10.2.2 INTRAVENOUS
• 10.3 ORAL
  • 10.3.1 TABLET
  • 10.3.2 CAPSULES
  • 10.3.3 OTHERS

11 EUROPE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE

• 11.1 OVERVIEW
• 11.2 PRESCRIPTION
• 11.3 OVER-THE-COUNTER (OTC)

12 EUROPE DENGUE TREATMENT MARKET, BY GENDER

• 12.1 OVERVIEW
• 12.2 MALE
• 12.3 FEMALE

13 EUROPE DENGUE TREATMENT MARKET, BY AGE

• 13.1 OVERVIEW
• 13.2 ADULT
• 13.3 PEDIATRIC
• 13.4 GERIATRIC

14 EUROPE DENGUE TREATMENT MARKET, BY END USER

• 14.1 OVERVIEW
• 14.2 HOSPITAL
• 14.3 SPECIALTY CLINICS
• 14.4 HOME HEALTHCARE
• 14.5 OTHERS

15 EUROPE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

• 15.1 OVERVIEW
• 15.2 RETAIL PHARMACIES
• 15.3 HOSPITAL PHARMACIES
• 15.4 ONLINE PHARMACIES

16 EUROPE DENGUE TREATMENT MARKET, BY REGION

• 16.1 EUROPE
  • 16.1.1 FRANCE
  • 16.1.2 GERMANY
  • 16.1.3 SPAIN
  • 16.1.4 U.K.
  • 16.1.5 BELGIUM
  • 16.1.6 ITALY
  • 16.1.7 NETHERLANDS
  • 16.1.8 RUSSIA
  • 16.1.9 SWITZERLAND
  • 16.1.10 TURKEY
  • 16.1.11 REST OF EUROPE

17 EUROPE DENGUE TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: EUROPE

18 SWOT ANALYSIS

19 COMPANY PROFILE

• 19.1 SANOFI
  • 19.1.1 COMPANY SNAPSHOT
  • 19.1.2 REVENUE ANALYSIS
  • 19.1.3 COMPANY SHARE ANALYSIS
  • 19.1.4 PRODUCT PORTFOLIO
  • 19.1.5 RECENT DEVELOPMENTS
• 19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • 19.2.1 COMPANY SNAPSHOT
  • 19.2.2 REVENUE ANALYSIS
  • 19.2.3 COMPANY SHARE ANALYSIS
  • 19.2.4 PRODUCT PORTFOLIO
  • 19.2.5 RECENT DEVELOPMENTS
• 19.3 VIATRIS INC.
  • 19.3.1 COMPANY SNAPSHOT
  • 19.3.2 REVENUE ANALYSIS
  • 19.3.3 COMPANY SHARE ANALYSIS
  • 19.3.4 PRODUCT PORTFOLIO
  • 19.3.5 RECENT DEVELOPMENTS
• 19.4 JOHNSON & JOHNSON SERVICES, INC.
  • 19.4.1 COMPANY SNAPSHOT
  • 19.4.2 REVENUE ANALYSIS
  • 19.4.3 COMPANY SHARE ANALYSIS
  • 19.4.4 PRODUCT PORTFOLIO
  • 19.4.5 RECENT DEVELOPMENT
• 19.5 GSK PLC.
  • 19.5.1 COMPANY SNAPSHOT
  • 19.5.2 REVENUE ANALYSIS
  • 19.5.3 COMPANY SHARE ANALYSIS
  • 19.5.4 PRODUCT PORTFOLIO
  • 19.5.5 RECENT DEVELOPMENTS
• 19.6 AUROBINDO PHARMA
  • 19.6.1 COMPANY SNAPSHOT
  • 19.6.2 REVENUE ANALYSIS
  • 19.6.3 PRODUCT PORTFOLIO
• 19.7 BAXTER
  • 19.7.1 COMPANY SNAPSHOT
  • 19.7.2 REVENUE ANALYSIS
  • 19.7.3 PRODUCT PORTFOLIO
• 19.8 FRESENIUS KABI USA
  • 19.8.1 COMPANY SNAPSHOT
  • 19.8.2 PRODUCT PORTFOLIO
  • 19.8.3 RECENT DEVELOPMENTS
• 19.9 HIKMA PHARMACEUTICALS
  • 19.9.1 COMPANY SNAPSHOT
  • 19.9.2 REVENUE ANALYSIS
  • 19.9.3 PRODUCT PORTFOLIO
  • 19.9.4 RECENT DEVELOPMENT
• 19.10 PERRIGO COMPANY PLC
  • 19.10.1 COMPANY SNAPSHOT
  • 19.10.2 REVENUE ANALYSIS
  • 19.10.3 PRODUCT PORTFOLIO
  • 19.10.4 RECENT DEVELOPMENT
• 19.11 PFIZER INC.
  • 19.11.1 COMPANY SNAPSHOT
  • 19.11.2 REVENUE ANALYSIS
  • 19.11.3 PRODUCT PORTFOLIO
  • 19.11.4 RECENT DEVELOPMENTS
• 19.12 SUN PHARMACEUTICAL INDUSTRIES LTD
  • 19.12.1 COMPANY SNAPSHOT
  • 19.12.2 REVENUE ANALYSIS
  • 19.12.3 PRODUCT PORTFOLIO
  • 19.12.4 RECENT DEVELOPMENT
• 19.13 TEVA PHARMACEUTICALS USA, INC.
  • 19.13.1 COMPANY SNAPSHOT
  • 19.13.2 REVENUE ANALYSIS
  • 19.13.3 PRODUCT PORTFOLIO
  • 19.13.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

LIST OF TABLES

• TABLE 1 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
• TABLE 2 IMPACT OF DELAY IN APPROVAL PROCESS
• TABLE 3 EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 4 EUROPE DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 5 EUROPE DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 6 EUROPE DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 7 EUROPE DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 8 EUROPE OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 9 EUROPE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 10 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 11 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 12 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 13 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 14 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 15 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 16 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 17 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 18 EUROPE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 19 EUROPE MILD TO MODERATE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 20 EUROPE SEVERE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 21 EUROPE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 22 EUROPE PARENTERAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 23 EUROPE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 24 EUROPE ORAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 25 EUROPE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 26 EUROPE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 27 EUROPE PRESCRIPTION IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 28 EUROPE OVER-THE-COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 29 EUROPE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 30 EUROPE MALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 31 EUROPE FEMALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 32 EUROPE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 33 EUROPE ADULT IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 34 EUROPE PEDIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 35 EUROPE GERIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 36 EUROPE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 37 EUROPE HOSPITAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 38 EUROPE SPECIALITY CLINICS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 39 EUROPE HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 40 EUROPE OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 41 EUROPE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 42 EUROPE RETAIL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 43 EUROPE HOSPITAL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 44 EUROPE ONLINE PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
• TABLE 45 EUROPE DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
• TABLE 46 EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 47 EUROPE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 48 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 49 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 50 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 51 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 52 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 53 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 54 EUROPE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 55 EUROPE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 56 EUROPE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 57 EUROPE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 58 EUROPE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 59 EUROPE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 60 EUROPE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 61 EUROPE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 62 EUROPE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 63 FRANCE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 64 FRANCE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 65 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 66 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 67 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 68 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 69 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 70 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 71 FRANCE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 72 FRANCE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 73 FRANCE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 74 FRANCE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 75 FRANCE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 76 FRANCE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 77 FRANCE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 78 FRANCE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 79 FRANCE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 80 GERMANY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 81 GERMANY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 82 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 83 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 84 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 85 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 86 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 87 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 88 GERMANY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 89 GERMANY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 90 GERMANY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 91 GERMANY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 92 GERMANY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 93 GERMANY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 94 GERMANY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 95 GERMANY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 96 GERMANY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 97 SPAIN DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 98 SPAIN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 99 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 100 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 101 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 102 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 103 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 104 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 105 SPAIN DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 106 SPAIN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 107 SPAIN PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 108 SPAIN ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 109 SPAIN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 110 SPAIN DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 111 SPAIN DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 112 SPAIN DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 113 SPAIN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 114 U.K. DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 115 U.K. DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 116 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 117 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 118 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 119 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 120 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 121 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 122 U.K. DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 123 U.K. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 124 U.K. PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 125 U.K. ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 126 U.K. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 127 U.K. DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 128 U.K. DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 129 U.K. DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 130 U.K. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 131 BELGIUM DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 132 BELGIUM DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 133 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 134 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 135 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 136 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 137 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 138 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 139 BELGIUM DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 140 BELGIUM DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 141 BELGIUM PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 142 BELGIUM ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 143 BELGIUM DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 144 BELGIUM DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 145 BELGIUM DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 146 BELGIUM DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 147 BELGIUM DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 148 ITALY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 149 ITALY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 150 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 151 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 152 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 153 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 154 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 155 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 156 ITALY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 157 ITALY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 158 ITALY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 159 ITALY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 160 ITALY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 161 ITALY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 162 ITALY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 163 ITALY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 164 ITALY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 165 NETHERLANDS DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 166 NETHERLANDS DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 167 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 168 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 169 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 170 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 171 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 172 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 173 NETHERLANDS DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 174 NETHERLANDS DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 175 NETHERLANDS PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 176 NETHERLANDS ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 177 NETHERLANDS DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 178 NETHERLANDS DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 179 NETHERLANDS DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 180 NETHERLANDS DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 181 NETHERLANDS DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 182 RUSSIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 183 RUSSIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 184 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 185 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 186 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 187 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 188 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 189 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 190 RUSSIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 191 RUSSIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 192 RUSSIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 193 RUSSIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 194 RUSSIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 195 RUSSIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 196 RUSSIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 197 RUSSIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 198 RUSSIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 199 SWITZERLAND DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 200 SWITZERLAND DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 201 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 202 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 203 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 204 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 205 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 206 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 207 SWITZERLAND DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 208 SWITZERLAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 209 SWITZERLAND PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 210 SWITZERLAND ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 211 SWITZERLAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 212 SWITZERLAND DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 213 SWITZERLAND DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 214 SWITZERLAND DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 215 SWITZERLAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 216 TURKEY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
• TABLE 217 TURKEY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 218 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 219 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 220 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 221 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 222 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
• TABLE 223 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
• TABLE 224 TURKEY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
• TABLE 225 TURKEY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
• TABLE 226 TURKEY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 227 TURKEY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
• TABLE 228 TURKEY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
• TABLE 229 TURKEY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
• TABLE 230 TURKEY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
• TABLE 231 TURKEY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
• TABLE 232 TURKEY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
• TABLE 233 REST OF EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

LIST OF FIGURES

• FIGURE 1 EUROPE DENGUE TREATMENT MARKET: SEGMENTATION
• FIGURE 2 EUROPE DENGUE TREATMENT MARKET: DATA TRIANGULATION
• FIGURE 3 EUROPE DENGUE TREATMENT MARKET: DROC ANALYSIS
• FIGURE 4 EUROPE DENGUE TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
• FIGURE 5 EUROPE DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
• FIGURE 6 EUROPE DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
• FIGURE 7 EUROPE DENGUE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
• FIGURE 8 EUROPE DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
• FIGURE 9 EUROPE DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
• FIGURE 10 EUROPE DENGUE TREATMENT MARKET: SEGMENTATION
• FIGURE 11 GROWING PHARMACEUTICAL INDUSTRY IS DRIVING THE GROWTH OF THE EUROPE DENGUE TREATMENT MARKET FROM 2024 TO 2031
• FIGURE 12 ON THE BASIS OF STRAINS, THE DENV-2 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DENGUE TREATMENT MARKET IN 2024 AND 2031
• FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE DENGUE TREATMENT MARKET
• FIGURE 14 FINANCIAL BUDGET FOR VECTOR-BORNE -DISEASES INCLUDING DENGUE IN INDIA
• FIGURE 15 EUROPE DENGUE TREATMENT MARKET: BY STRAINS, 2023
• FIGURE 16 EUROPE DENGUE TREATMENT MARKET: BY STRAINS, 2024-2031 (USD MILLION)
• FIGURE 17 EUROPE DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2024-2031)
• FIGURE 18 EUROPE DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
• FIGURE 19 EUROPE DENGUE TREATMENT MARKET: BY TYPE, 2023
• FIGURE 20 EUROPE DENGUE TREATMENT MARKET: BY TYPE, 2024-2031 (USD MILLION)
• FIGURE 21 EUROPE DENGUE TREATMENT MARKET: BY TYPE, CAGR (2024-2031)
• FIGURE 22 EUROPE DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
• FIGURE 23 EUROPE DENGUE TREATMENT MARKET: BY SEVERITY, 2023
• FIGURE 24 EUROPE DENGUE TREATMENT MARKET: BY SEVERITY, 2024-2031 (USD MILLION)
• FIGURE 25 EUROPE DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2024-2031)
• FIGURE 26 EUROPE DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
• FIGURE 27 EUROPE DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023
• FIGURE 28 EUROPE DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
• FIGURE 29 EUROPE DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
• FIGURE 30 EUROPE DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
• FIGURE 31 EUROPE DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2023
• FIGURE 32 EUROPE DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
• FIGURE 33 EUROPE DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2024-2031)
• FIGURE 34 EUROPE DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
• FIGURE 35 EUROPE DENGUE TREATMENT MARKET: BY GENDER, 2023
• FIGURE 36 EUROPE DENGUE TREATMENT MARKET: BY GENDER, 2024-2031 (USD MILLION)
• FIGURE 37 EUROPE DENGUE TREATMENT MARKET: BY GENDER, CAGR (2024-2031)
• FIGURE 38 EUROPE DENGUE TREATMENT MARKET: BY GENDER, LIFELINE CURVE
• FIGURE 39 EUROPE DENGUE TREATMENT MARKET: BY AGE, 2023
• FIGURE 40 EUROPE DENGUE TREATMENT MARKET: BY AGE, 2024-2031 (USD MILLION)
• FIGURE 41 EUROPE DENGUE TREATMENT MARKET: BY AGE, CAGR (2024-2031)
• FIGURE 42 EUROPE DENGUE TREATMENT MARKET: BY AGE, LIFELINE CURVE
• FIGURE 43 EUROPE DENGUE TREATMENT MARKET: BY END USER, 2023
• FIGURE 44 EUROPE DENGUE TREATMENT MARKET: BY END USER, 2024-2031 (USD MILLION)
• FIGURE 45 EUROPE DENGUE TREATMENT MARKET: BY END USER, CAGR (2024-2031)
• FIGURE 46 EUROPE DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
• FIGURE 47 EUROPE DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023
• FIGURE 48 EUROPE DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
• FIGURE 49 EUROPE DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
• FIGURE 50 EUROPE DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
• FIGURE 51 EUROPE DENGUE TREATMENT MARKET: SNAPSHOT (2023)
• FIGURE 52 EUROPE DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)